Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-25 vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA),Breakthrough pain in cancer patients (off-label),Anesthesia (off-label)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized via CYP3A4 to norfentanyl (major inactive metabolite) and other minor metabolites.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
~80-85% bound to plasma proteins (mainly albumin, also alpha-1-acid glycoprotein)
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
6-10 L/kg (large, indicating extensive tissue distribution; Vd 6.4 L/kg in adults)
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Transdermal: ~92% absolute bioavailability (fentanyl absorbed through skin; compared to IV administration)
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
For GFR 10-50 m L/min: start with 12 mcg/hour patch; for GFR <10 m L/min: avoid use due to accumulation of active metabolite; consider alternative therapy.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A or B: reduce starting dose by 50% (e.g., start with 12 mcg/hour); Child-Pugh Class C: avoid use or use with extreme caution and close monitoring.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
For children aged 2-16 years: initial dose based on opioid tolerance; typical starting dose for opioid-naive: 25 mcg/hour transdermal patch every 72 hours is not recommended; use lower strength or immediate-release opioids; refer to institutional guidelines.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lowest available strength (12 mcg/hour) and titrate cautiously; monitor for respiratory depression and constipation; avoid in frail elderly if possible.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DURAGESIC. Ensure accuracy when prescribing, dispensing, and administering DURAGESIC. Dosage errors can result in accidental overdose or death. Concomitant use with CYP3A4 inhibitors, potent CYP3A4 inducers, or the cessation of CYP3A4 inducers can cause fatal respiratory depression. DURAGESIC is contraindicated in opioid-non-tolerant patients and in acute or postoperative pain.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Life-threatening respiratory depression,Accidental exposure to children,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Adrenal insufficiency,Hypotension and bradycardia,Severe hypotension,Risks in patients with gastrointestinal obstruction,Seizures in patients with seizure disorders,Life-threatening QT prolongation at high doses
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Opioid non-tolerant patients,Acute or short-term pain,Postoperative pain,Significant respiratory depression,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction,Known hypersensitivity to fentanyl or any component of the system
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they increase the risk of respiratory depression and sedation. No specific food interactions; however, grapefruit juice may theoretically increase fentanyl levels via CYP3A4 inhibition, but clinical significance is minimal. Advise patients to maintain consistent dietary habits.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid unless benefits outweigh risks.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Fentanyl is excreted in breast milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure with maternal therapeutic doses, but risk of sedation/respiratory depression in infants. Use with caution; monitor infant for drowsiness and feeding difficulties.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No established dose changes; pharmacokinetics in pregnancy show increased clearance and volume of distribution. Individualize dosing based on pain severity and response; monitor for under- or overdosing. Titrate to effect with caution.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
DURAGESIC-25 delivers fentanyl at 25 mcg/h transdermally. The reservoir system may leak if cut, potentially causing fatal overdose. Apply to non-irritated, non-hairy skin on upper torso. Do not apply heat sources (heating pads, hot tubs) as they increase absorption rate. Onset of action is 12-24 hours; titrate no more frequently than every 3 days. Use only in opioid-tolerant patients due to risk of respiratory depression. Monitor for serotonin syndrome if co-administering serotonergic drugs.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Apply the patch to clean, dry, non-hairy skin on the upper body; change every 72 hours.,Do not cut, tear, or damage the patch; do not use if the pouch seal is broken.,Avoid exposing the patch area to direct heat sources such as heating pads, electric blankets, hot tubs, or prolonged sun exposure.,Keep patches out of reach of children and pets; dispose of used patches by folding adhesive sides together and flushing down the toilet.,Do not stop using this medication abruptly; withdrawal may occur.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-25 vs ACTIQ, answered by our medical review team.
DURAGESIC-25 is a Opioid Analgesic that works by Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-25 and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-25 is: Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-25 and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-25 is classified as Category C. First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal s. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.